Use of thiopurines in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 19, Issue 7, 2013, Pages 1040-1048

  Frei, Pascal ^a   Biedermann, Luc ^a   Nielsen, Ole Haagen ^b   Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Crohn's disease; Immunosuppression; Infection; Inflammatory bowel disease; Thiopurines; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALLOPURINOL; AZATHIOPRINE; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TUMOR NECROSIS FACTOR INHIBITOR;

ALOPECIA; AMYLASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEVER; HEADACHE; HEPATITIS; HUMAN; INFECTIOUS COMPLICATION; LACTATION; LIVER FIBROSIS; LIVER TOXICITY; MUSCLE WEAKNESS; MYALGIA; NODULAR HYPERPLASIA; NON MELANOMA SKIN CANCER; PANCREATITIS; POSTOPERATIVE CARE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; STOMATITIS; T CELL LYMPHOMA; ULCERATIVE COLITIS; WEIGHT REDUCTION;

EID: 84874360621     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i7.1040     Document Type: Review

References (99)

1. Watanabe A, Hobara N, Nagashima H. Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine. Acta Med Okayama 1978; 32: 173-179 [PMID: 29442 DOI: 10.1097/00007691-199810000-00002]
2. Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther Drug Monit 1998; 20: 459-463 [PMID: 9780118]
3. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004; 33: 209-234, viii [PMID: 15177535 DOI: 10.1016/j.gtc.2004.02.004 DOI: 10.1053/j.gastro.2006.01.047]
4. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 935-939 [PMID: 16530531]
5. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4: 28-62 [PMID: 21122489 DOI: 10.1016/ j.crohns.2009.12.002]
6. Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008; 23: 1373-1377 [PMID: 18662197 DOI: 10.1111/ j.1440-1746.2008.05419.x]
7. Komiyama T, Yajima T, Kubota R, Iwao Y, Sakuraba A, Funakoshi S, Negishi K, Minami I, Tanaka Y, Mae H, Hibi T. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohns Colitis 2008; 2: 315-321 [PMID: 21172230 DOI: 10.1016/j.crohns.2008.05.002]
8. Ohtsuka Y, Arai K, Aoyagi Y, Fujii T, Yamakawa Y, Ohtani K, Ikuse T, Baba Y, Inage E, Kudo T, Suzuki R, Nagata S, Shimizu T. Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease. J Gastroenterol Hepatol 2010; 25: 1626-1630 [PMID: 20880170 DOI: 10.1111/j.1440-1746.2010.06364.x]
9. Seinen ML, van Asseldonk DP, Mulder CJ, de Boer NK. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. J Gastrointestin Liver Dis 2010; 19: 291-294 [PMID: 20922194]
10. Derijks LJ, Gilissen LP, de Boer NK, Mulder CJ. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent? J Hepatol 2006; 44: 821-822 [PMID: 16487623 DOI: 10.1016/j.jhep.2005.11.049]
11. Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrügger RW, Engels LG. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with longterm, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig Liver Dis 2007; 39: 156-159 [PMID: 17188950 DOI: 10.1016/j.dld.2006.10.007]
12. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol 2010; 24: 157-165 [PMID: 20227029 DOI: 10.1016/j.bpg.2009.10.011]
13. de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis 2008; 40: 108-113 [PMID: 18083079 DOI: 10.1016/ j.dld.2007.10.013]
14. Jharap B, van Asseldonk DP, de Boer NK, Colombel JF, Diebold J, Jonker AM, Leteurtre E, Reinisch W, VernierMassouille G, Wendum D, Wrba F, Zondervan PE, Mulder CJJ, van Bodegraven AA, Bloemena E. Low Inter-Observer Agreement on Nodular Regenerative Hyperplasia of the Liver: An European Inter-Observer Analysis. Gastroenterology 2010; 138: S456 [DOI: 10.1016/S0016-5085(10)62112-9]
15. Zech CJ, Seiderer J, Reinisch W, Ochsenkuhn T, Schima W, Diebold J, Wrba F, Reiser MF, Schoenberg SO. Thioguanininduced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques. Eur Radiol 2007; 17: 1898-1905 [PMID: 17221208 DOI: 10.1007/s00330-006-0544-3]
16. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19-52 [PMID: 10331075 DOI: 10.1146/annurev.pharmtox.39.1.19]
17. Kubota T, Nishida A, Takeuchi K, Iida T, Yokota H, Higashi K, Nakahara K, Hanai H, Iga T. Frequency distribution of thiopurine S-methyltransferase activity in red blood cells of a healthy Japanese population. Ther Drug Monit 2004; 26: 319-321 [PMID: 15167635 DOI: 10.1097/00007691-200406000 -00017]
18. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 15-36 [PMID: 22050052 DOI: 10.1111/j.1365-2036.2011.04905.x]
19. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 1009-1014 [PMID: 10930894 DOI: 10.1046/j.1365-2036.2000.00812.x]
20. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-1053 [PMID: 16618398]
21. Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, Romberg-Camps MJ, Stronkhorst A, Bus P, Bos LP, Hooymans PM, Stockbrügger RW, Neef C, Masclee AA. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis 2012; 6: 698-707 [PMID: 22398098 DOI: 10.1016/j.crohns.2011.12.003]
22. Rayner CK, Hart AL, Hayward CM, Emmanuel AV, Kamm MA. Azathioprine dose escalation in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 65-71 [PMID: 15225172 DOI: 10.1111/j.1365-2036.2004.02009.x]
23. Bondesen S, Nielsen OH, Schou JB, Jensen PH, Lassen LB, Binder V, Krasilnikoff PA, Danø P, Hansen SH, Rasmussen SN. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis. Scand J Gastroenterol 1986; 21: 693-700 [PMID: 2875518 DOI: 10.3109/00365528609011102]
24. de Graaf P, de Boer NK, Wong DR, Karner S, Jharap B, Hooymans PM, Veldkamp AI, Mulder CJ, van Bodegraven AA, Schwab M. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol 2010; 160: 1083-1091 [PMID: 20590602 DOI: 10.1111/ j.1476-5381.2010.00731.x]
25. Hindorf U, Appell ML. Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. J Crohns Colitis 2012; 6: 655-659 [PMID: 22398041 DOI: 10.1016/j.crohns.2011.11.014]
26. Booth RA, Ansari MT, Loit E, Tricco AC, Weeks L, Doucette S, Skidmore B, Sears M, Sy R, Karsh J. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011; 154: 814-23, W-295-8 [PMID: 21690596]
27. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89: 387-391 [PMID: 21270794 DOI: 10.1038/clpt.2010.320]
28. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soulé JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-1030 [PMID: 10833476]
29. Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99: 878-883 [PMID: 15128354 DOI: 10.1111/ j.1572-0241.2004.04148.x]
30. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-433 [PMID: 8633486]
31. Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Schölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005; 32: 1473-1480 [PMID: 16078322]
32. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 630-642 [PMID: 21407186 DOI: 10.1038/ajg.2011.64]
33. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678 [PMID: 8549944 DOI: 10.1136/gut.37.5.674]
34. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Meyer zum Büschenfelde KH. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 367-372 [PMID: 8335191]
35. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin C, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Villa Y, Arber N, Gilat T. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-2209 [PMID: 9399753]
36. Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008; 103: 2284-2292 [PMID: 18671816 DOI: 10.1111/j.1572-0241.2008.02024.x]
37. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 278-282 [PMID: 7876505 DOI: 10.1097/00004836-199412000-00003]
38. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-630 [PMID: 4441827 DOI: 10.1136/bmj.4.5945.627]
39. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000; 19: 14-16 [PMID: 10659481]
40. Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-1818 [PMID: 15940616 DOI: 10.1053/ j.gastro.2005.03.031]
41. O'Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955-957 [PMID: 81986 DOI: 10.1016/S01406736(78)92524-2]
42. Vilien M, Dahlerup JF, Munck LK, Nørregaard P, Grønbaek K, Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn' s disease: increased relapse rate the following year. Aliment Pharmacol Ther 2004; 19: 1147-1152 [PMID: 15153167 DOI: 10.1111/j.1365-2036.2004.01944.x]
43. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975; 20: 721-726 [PMID: 1098449 DOI: 10.1007/BF01070829]
44. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 270-274 [PMID: 11993510 DOI: 10.1007/s005350200034]
45. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-22 [PMID: 1638191 DOI: 10.1136/ bmj.305.6844.20]
46. D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135: 1123-1129 [PMID: 18727929 DOI: 10.1053/ j.gastro.2008.07.010]
47. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-729 [PMID: 15362027 DOI: 10.1053/j.gastro.2004.06.002]
48. Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104: 2089-2096 [PMID: 19568226 DOI: 10.1038/ajg.2009.301]
49. Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Teml A, Schaeffeler E, Schwab M, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59: 752-759 [PMID: 20551460 DOI: 10.1136/ gut.2009.194159]
50. De Cruz P, Kamm M, Hamilton AL, Ritchie K, Gorelik A, Liew D, Prideaux L, Lawrance I, Andrews JM, Bampton P, Sparrow M, Jakobovits S, Florin T, Gibson P, Debinski H, Gearry R, Macrae F, Leong R I. K, Connor S, Pavli P, Radford-Smith G, Selby W, Johnston M, Brouwer R, Keck JO, Woods R, Connell W, Brown SJ, Bell SJ, Lust M, Elliott R, Desmond PV. Adalimumab prevents post-operative Crohn' s disease recurrence, and is superior to thiopurines: Early results from the prospective POCER study. J Crohns Colitis 2012; 6 Suppl 1: S146 [DOI: 10.1016/S1873-9946(12)60361-4]
51. Swoger JM, Regueiro M. Postoperative Crohn's disease: how can we prevent it? Expert Rev Clin Immunol 2010; 6: 501-504 [PMID: 20594119 DOI: 10.1586/eci.10.33]
52. Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr 2007; 119: 519-526 [PMID: 17943403 DOI: 10.1007/s00508-007-0841-0]
53. Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2009; 6: 92-106 [PMID: 19153563 DOI: 10.1038/ncpgasthep1340]
54. Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-1549 [PMID: 20155846 DOI: 10.1002/ibd.21221]
55. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 331-342 [PMID: 16842460 DOI: 10.1111/j.1365-2036.2006.02977.x]
56. Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 654-661 [PMID: 19183142 DOI: 10.1111/j.1365-2036.2008.03925.x]
57. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-1252 [PMID: 7910274 DOI: 10.1016/ S0140-6736(94)92150-4]
58. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: shortand long-term toxicity. Ann Intern Med 1989; 111: 641-649 [PMID: 2802419]
59. Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2005; 39: 21-26 [PMID: 15599205]
60. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with shortand long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003; 37: 220-225 [PMID: 12960720 DOI: 10.1097/00004836-200309000-00006]
61. Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A, Duclos B, Seksik P, Mary JY, Colombel JF. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007; 56: 1404-1409 [PMID: 17504943 DOI: 10.1136/gut.2006.114363]
62. De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol 2008; 43: 604-608 [PMID: 18415755 DOI: 10.1080/00365520701800266]
63. Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-1128 [PMID: 15247179 DOI: 10.1136/gut.2003.032896]
64. Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprineintolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 220-227 [PMID: 17988235 DOI: 10.1111/j.1365-2036.2007.03570.x]
65. de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 686-694 [PMID: 18043678 DOI: 10.1038/ncpgasthep1000]
66. Grassia R, Paolo Coppeta G, Staiano T. Severe muscular weakness as an isolated symptom of azathioprine hypersensitivity. Inflamm Bowel Dis 2011; 17: E61 [PMID: 21472829 DOI: 10.1002/ibd.21715]
67. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485 [PMID: 12890847 DOI: 10.1056/NEJMra021844]
68. Costantino G, Furfaro F, Belvedere A, Alibrandi A, Fries W. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in followup. J Crohns Colitis 2012; 6: 588-596 [PMID: 22398045 DOI: 10.1016/j.crohns.2011.11.007]
69. Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17: 4166-4173 [PMID: 22072847 DOI: 10.3748/wjg.v17.i37.4166]
70. Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 Suppl 1: i16-i35 [PMID: 16481629 DOI: 10.1136/gut.2005.081950b]
71. Chocair P, Duley J, Simmonds HA, Cameron JS, Ianhez L, Arap S, Sabbaga E. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993; 342: 83-84 [PMID: 8100914 DOI: 10.1016/0140-6736(93)91287-V]
72. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-647 [PMID: 20015102 DOI: 10.1111/j.1365-2036.2009.04221.x]
73. Shih DQ, Nguyen M, Ibanez P, Kwan LY, Targan SR, Vasiliauskas EA. Split-dose administration of 6MP/Azathiopurine: a novel and effective strategy for IBD patients with preferential 6MMP metabolism. Gastroenterology 2009; 136: A677-A678 [DOI: 10.1016/S0016-5085(09)63119-X]
74. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-1125 [PMID: 16009685 DOI: 10.1136/gut.2004.049460]
75. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41. e1 [PMID: 20888436]
76. Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2063-2071 [PMID: 22271569 DOI: 10.1002/ibd.22889]
77. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010; 105: 1604-1609 [PMID: 20104215 DOI: 10.1038/ajg.2009.745]
78. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-274 [PMID: 20005977 DOI: 10.1016/j.cgh.2009.11.024]
79. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390-399.e1 [PMID: 22584081]
80. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-28.e1-5 [PMID: 21708105]
81. Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012; 18: 174-179 [PMID: 21674731 DOI: 10.1002/ibd.21792]
82. Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999; 94: 3254-3257 [PMID: 10566725 DOI: 10.1111/j.1572-0241.1999.01532.x]
83. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-85 [PMID: 18849016 DOI: 10.1016/ j.cgh.2008.08.028]
84. Cassinotti A, Actis GC, Duca P, Massari A, Colombo E, Gai E, Annese V, D'Albasio G, Manes G, Travis S, Porro GB, Ardizzone S. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009; 104: 2760-2767 [PMID: 19623172 DOI: 10.1038/ajg.2009.410]
85. Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004; 99: 462-465 [PMID: 15056086 DOI: 10.1111/j.1572-0241. 2004.04104.x]
86. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]
87. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667 [PMID: 18295023]
88. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061 [PMID: 16618399 DOI: 10.1053/j.gastro.2006.02.014]
89. Reenaers C, Louis E, Belaiche J, Keshav S, Travis S. Immunosuppressive co-treatment with adalimumab (ADA) may be more effective than ADA monotherapy for maintaining remission in Crohn's disease (CD). J Crohns Colitis 2012; 6 Suppl 1: S8 [DOI: 10.1016/S1873-9946(12)60016-6]
90. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226 [PMID: 19392858 DOI: 10.1111/j.1365-2036.2009.04027.x]
91. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. Withdrawal of immunosuppression in Crohn' s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868 [PMID: 18440315 DOI: 10.1053/j.gastro.2008.03.004]
92. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.e5; quiz e31 [PMID: 21945953]
93. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010; 105: 1142-1149 [PMID: 20389296]
94. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17 [PMID: 12512024 DOI: 10.1053/gast.2003.50014]
95. Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, Malm H, Reuvers-Lodewijks ME, Rost van Tonningen-van Driel MM, Arnon J, Ornoy A, Clementi M, Di Gianantonio E, Koren G, Braunstein R, Berkovitch M. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696-701 [PMID: 17847119 DOI: 10.1002/ bdra.20399]
96. Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85: 647-654 [PMID: 19343728 DOI: 10.1002/bdra.20583]
97. Langagergaard V, Pedersen L, Gislum M, Nørgard B, Sørensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: A Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81 [PMID: 17229222 DOI: 10.1002/bdra.20583]
98. Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28: 1209-1213 [PMID: 18761704]
99. Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP. The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. Aliment Pharmacol Ther 2011; 33: 707-713 [PMID: 21251032 DOI: 10.1111/j.1365-2036.2011.04577.x]